Grant Yonehiro is listed as an executive officer on 5 SEC Form D filings by 1 issuer between Feb 2018 and Jun 2021: Bolt Biotherapeutics, Inc. (Redwood City, CA — biotechnology — 2018–2021; $93.5M reported sold to 17 investors).
What this means One deal on file with the SEC. A Form D is the notice a company files after it starts selling a private investment — it is a notice, not an approval.
Listed alongside Edgar Engleman (5 shared filings), Mahendra Shah (5 shared filings), Ashish Khanna (4 shared filings), Peter Moldt (4 shared filings), Richard Miller (3 shared filings) and 7 others.
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Grant. Each name links to their own page.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AZ, CA, DE, TX, WA) — none found.
What this means Nothing turned up where we looked (3 sources). That does not prove there is nothing — it means none was found in those sources on that date.
We compared 5 public filings for Grant Yonehiro and found 2 differences, 1 worth asking the sponsor about: Form D filed 216 days after the first sale; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.